NCT03910231View on ClinicalTrials.gov

The Role of Vasopressin Antagonism on Renal Sodium Handling

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 1, 2012

Primary Completion Date

September 30, 2014

Study Completion Date

February 1, 2015

Conditions
Healthy
Interventions
DRUG

Tolvaptan Oral Tablet

Tolvaptan, to block V2R

Sponsors
All Listed Sponsors
collaborator

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

lead

Brigham and Women's Hospital

OTHER

NCT03910231 - The Role of Vasopressin Antagonism on Renal Sodium Handling | Biotech Hunter | Biotech Hunter